Belarus vs Morocco: Average cost of drugs for extensively drug-resistant tuberculosis
Belarus
4,600 constant 2022 US$
in 2023
Morocco
4,500 constant 2022 US$
in 2024
Belarus rank
13th
Morocco rank
14th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Belarus
- Morocco
How they compare
Belarus currently reports 4,600 constant 2022 US$ against 4,500 constant 2022 US$ in Morocco, a difference of 100 constant 2022 US$.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Belarus ahead.
Belarus ranks 13th and Morocco ranks 14th of 56 countries.
Belarus has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Belarus | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,617 constant 2022 US$ | 7,423 constant 2022 US$ | 193.33 constant 2022 US$ | Belarus |
| 2020s | 5,867 constant 2022 US$ | 3,705 constant 2022 US$ | 2,162 constant 2022 US$ | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Belarus or Morocco?
- Belarus, at 4,600 constant 2022 US$ against 4,500 constant 2022 US$ in Morocco as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Belarus and Morocco?
- 100 constant 2022 US$, with Belarus ahead.
- How many years of comparable data are there for Belarus and Morocco?
- 6 years are reported by both, from 2017 to 2023.
- How do Belarus and Morocco rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Belarus ranks 13th and Morocco ranks 14th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.